Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma's CEO Bruce Cozadd
Source: Life Science Leader
By Ben Comer, Chief Editor, Life Science Leader
Jazz Pharmaceuticals’ $7.2 billion acquisition of GW Pharmaceuticals in 2021 nearly doubled the company’s headcount and placed it at the vanguard of cannabinoid companies. With the FDA approval of Epidiolex (cannabidiol) in 2018, GW Pharma became the first company to bring a prescription drug derived from marijuana plants to market.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more